Compensation 990
OrganizationsEmployeesBoard MembersGrantsContractorsTop RankingsPricing

Stay updated on 990 organization compensation

© Civic Register LLC

Compensation 990 is an independent service that uses public IRS Form 990 filings as its source data. We clean and standardize this information, but the original filings may contain errors or omissions. Years on this site refer to the organization’s fiscal year end date on the filing.

About•Report a discrepancy•Your privacy choices
Organizations Philanthropy, Voluntarism & Grantmaking Alliance for Cancer Gene Therapy Inc.

Alliance for Cancer Gene Therapy Inc.

Fiscal year ending 2025. Filed on September 11, 2025.

96 Cummings Point Road
Building
Stamford, Connecticut 06902

Alliance for Cancer Gene Therapy Inc. (EIN: 06-1619523) has filed an IRS Form 990 since fiscal year 2021. In its fiscal year 2025 IRS Form 990 filing, Alliance for Cancer Gene Therapy Inc., a 501(c)(3) charitable organization, reported compensation for 4 employees. Among the employees shown here, the average compensation is $248,302. The highest compensated employee at Alliance for Cancer Gene Therapy Inc. is Barbara Lavery with fiscal year 2025 compensation of $273,222.

Revenue, expenses, and employee compensation

Revenue

$3,103,520

Expenses

$5,355,546

Employee compensation

$581,564
Revenue, expenses, and employee compensation over time

Reported Compensated Employees

Barbara Lavery
Chief Program Officer
$273,222
$264,230 No related comp$8,992
Keri Eisenberg
Chief Philanthropy Officer
$223,382
$215,301 No related comp$8,081
H William Smith
Vice President Legal and Secretary
$0
Christine Herman
Vice President Treas(Thru 5/31/25)
$0

Benchmark Employee Compensation

Non-Employee Board Members

Alexandra Landes
Director
Barbara Netter
Director, Honorary Chairman
Bruce L Levine, Ph.D.
Director
Chau Q Khuong
Director
Chen Schor
Director
Daniel Englander
Director
Gbola Amusa
Director (Thru 6/27/24)
John C Sites Jr
Director
John Lahey, Ph.D.
Director
Kevin Honeycutt
President and Chief Executive Officer
Klaus R Veitinger, M.D., Ph.D.
Director
Marc Engelsgjerd, M.D.
Director (EFF 12/5/24)

Mission Statement

ACGT SUPPORTS HIGH-RISK, HIGH-REWARD SCIENTIFIC RESEARCH TO DEVELOP CANCER THERAPEUTICS THAT USE THE BODY'S OWN CELLS AND GENES AS A LIVING MEDICINE. BY ACCELERATING THIS RESEARCH, ACGT IS HELPING TO ADVANCE THERAPIES THAT ARE SIGNIFICANTLY MORE EFFECTIVE AND LESS TOXIC THAN CURRENT CANCER TREATMENTS SUCH AS CHEMOTHERAPY AND RADIATION.

Revisions to this organization profile

September 11, 2025:
2025 Alliance for Cancer Gene Therapy Inc. 990 filed
February 25, 2025:
2024 Alliance for Cancer Gene Therapy Inc. 990 filed
January 22, 2024:
2023 Alliance for Cancer Gene Therapy Inc. 990 filed

Get an email when new compensation information is released for Alliance for Cancer Gene Therapy Inc.

Be the first to know when new IRS Form 990 data is published for this organization.

Related Jobs

View more jobs
Powered by Talroo
Report a discrepancy →